Title : Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Pub. Date : 2019 Dec

PMID : 31591063






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTERPRETATION: Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. erlotinib epidermal growth factor receptor Homo sapiens